Cargando…

Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study

BACKGROUND: Advanced glycation end-products play a role in diabetic vascular complications. Their optical properties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searched for an association between SAF and major adverse cardiovascular events (MACE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanc-Bisson, C., Velayoudom-Cephise, F. L., Cougnard-Gregoire, A., Helmer, C., Rajaobelina, K., Delcourt, C., Alexandre, L., Blanco, L., Mohammedi, K., Monlun, M., Rigalleau, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993997/
https://www.ncbi.nlm.nih.gov/pubmed/29884175
http://dx.doi.org/10.1186/s12933-018-0718-8
_version_ 1783330329849757696
author Blanc-Bisson, C.
Velayoudom-Cephise, F. L.
Cougnard-Gregoire, A.
Helmer, C.
Rajaobelina, K.
Delcourt, C.
Alexandre, L.
Blanco, L.
Mohammedi, K.
Monlun, M.
Rigalleau, V.
author_facet Blanc-Bisson, C.
Velayoudom-Cephise, F. L.
Cougnard-Gregoire, A.
Helmer, C.
Rajaobelina, K.
Delcourt, C.
Alexandre, L.
Blanco, L.
Mohammedi, K.
Monlun, M.
Rigalleau, V.
author_sort Blanc-Bisson, C.
collection PubMed
description BACKGROUND: Advanced glycation end-products play a role in diabetic vascular complications. Their optical properties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searched for an association between SAF and major adverse cardiovascular events (MACE) incidence in subjects with Type 1 Diabetes (T1D) during a 7 year follow-up. METHODS: During year 2009, 232 subjects with T1D were included. SAF measurement, clinical [age, sex, body mass index (BMI), comorbidities] and biological data (HbA1C, blood lipids, renal parameters) were recorded. MACE (myocardial infarction, stroke, lower extremity amputation or a revascularization procedure) were registered at visits in the center or by phone call to general practitioners until 2016. RESULTS: The participants were mainly men (59.5%), 51.5 ± 16.7 years old, with BMI 25.0 ± 4.1 kg/m(2), diabetes duration 21.5 ± 13.6 years, HbA1C 7.6 ± 1.1%. LDL cholesterol was 1.04 ± 0.29 g/L, estimated Glomerular Filtration Rates (CKD-EPI): 86.3 ± 26.6 ml/min/1.73 m(2). Among these subjects, 25.1% were smokers, 45.3% had arterial hypertension, 15.9% had elevated AER (≥ 30 mg/24 h), and 9.9% subjects had a history of previous MACE. From 2009 to 2016, 22 patients had at least one new MACE: 6 myocardial infarctions, 1 lower limb amputation, 15 revascularization procedures. Their SAF was 2.63 ± 0.73 arbitrary units (AU) vs 2.08 ± 0.54 for other patients (p = 0.002). Using Cox-model, after adjustment for age (as the scale time), sex, diabetes duration, BMI, hypertension, smoking status, albumin excretion rates, statin treatment and a previous history of MACE, higher baseline levels of SAF were significantly associated with an increased risk of MACE during follow-up (HR = 4.13 [1.30–13.07]; p = 0.02 for 1 AU of SAF) and Kaplan–Meier curve follow-up showed significantly more frequent MACE in group with SAF upper the median (p = 0.001). CONCLUSION: A high SAF predicts MACE in patients with T1D. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0718-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5993997
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59939972018-07-05 Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study Blanc-Bisson, C. Velayoudom-Cephise, F. L. Cougnard-Gregoire, A. Helmer, C. Rajaobelina, K. Delcourt, C. Alexandre, L. Blanco, L. Mohammedi, K. Monlun, M. Rigalleau, V. Cardiovasc Diabetol Original Investigation BACKGROUND: Advanced glycation end-products play a role in diabetic vascular complications. Their optical properties allow to estimate their accumulation in tissues by measuring the skin autofluorescence (SAF). We searched for an association between SAF and major adverse cardiovascular events (MACE) incidence in subjects with Type 1 Diabetes (T1D) during a 7 year follow-up. METHODS: During year 2009, 232 subjects with T1D were included. SAF measurement, clinical [age, sex, body mass index (BMI), comorbidities] and biological data (HbA1C, blood lipids, renal parameters) were recorded. MACE (myocardial infarction, stroke, lower extremity amputation or a revascularization procedure) were registered at visits in the center or by phone call to general practitioners until 2016. RESULTS: The participants were mainly men (59.5%), 51.5 ± 16.7 years old, with BMI 25.0 ± 4.1 kg/m(2), diabetes duration 21.5 ± 13.6 years, HbA1C 7.6 ± 1.1%. LDL cholesterol was 1.04 ± 0.29 g/L, estimated Glomerular Filtration Rates (CKD-EPI): 86.3 ± 26.6 ml/min/1.73 m(2). Among these subjects, 25.1% were smokers, 45.3% had arterial hypertension, 15.9% had elevated AER (≥ 30 mg/24 h), and 9.9% subjects had a history of previous MACE. From 2009 to 2016, 22 patients had at least one new MACE: 6 myocardial infarctions, 1 lower limb amputation, 15 revascularization procedures. Their SAF was 2.63 ± 0.73 arbitrary units (AU) vs 2.08 ± 0.54 for other patients (p = 0.002). Using Cox-model, after adjustment for age (as the scale time), sex, diabetes duration, BMI, hypertension, smoking status, albumin excretion rates, statin treatment and a previous history of MACE, higher baseline levels of SAF were significantly associated with an increased risk of MACE during follow-up (HR = 4.13 [1.30–13.07]; p = 0.02 for 1 AU of SAF) and Kaplan–Meier curve follow-up showed significantly more frequent MACE in group with SAF upper the median (p = 0.001). CONCLUSION: A high SAF predicts MACE in patients with T1D. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0718-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-08 /pmc/articles/PMC5993997/ /pubmed/29884175 http://dx.doi.org/10.1186/s12933-018-0718-8 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Blanc-Bisson, C.
Velayoudom-Cephise, F. L.
Cougnard-Gregoire, A.
Helmer, C.
Rajaobelina, K.
Delcourt, C.
Alexandre, L.
Blanco, L.
Mohammedi, K.
Monlun, M.
Rigalleau, V.
Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
title Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
title_full Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
title_fullStr Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
title_full_unstemmed Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
title_short Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
title_sort skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993997/
https://www.ncbi.nlm.nih.gov/pubmed/29884175
http://dx.doi.org/10.1186/s12933-018-0718-8
work_keys_str_mv AT blancbissonc skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT velayoudomcephisefl skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT cougnardgregoirea skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT helmerc skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT rajaobelinak skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT delcourtc skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT alexandrel skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT blancol skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT mohammedik skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT monlunm skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy
AT rigalleauv skinautofluorescencepredictsmajoradversecardiovasculareventsinpatientswithtype1diabetesa7yearfollowupstudy